指定 against K.K. Heriosu
株式会社ヘリオス (Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices)
Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical DevicesMinistry of Health, Labour and WelfareFebruary 28, 2017
Action summary
- Company
- K.K. HeriosuRomanizedOriginal: 株式会社ヘリオス
- Governing law
- Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices薬機法
- Action type
- 指定指定
- Action date
- February 28, 2017
- Issuing authority
- Ministry of Health, Labour and Welfare厚生労働省
Violation
Show original Japanese text
急性期（発症後18～36時間）の脳梗塞の治療を目的とした、ドナーの骨髄から採取して増殖させた成人接着性幹細胞に由来する幹細胞製品。
Source
Original Ministry of Health, Labour and Welfare announcement (in Japanese)The original Japanese disclosure is the authoritative record.
Watch this company
Get an email when K.K. Heriosu has new enforcement actions or registry changes (representative, address, business status). Sign-in is via a one-time email link — no password.
Language
日本語版を見る (Japanese)About this recordAggregated and translated from public Japanese government disclosures. The English text is for reference only — authoritative content is the linked Japanese source.